Gene News and Research

Latest Gene News and Research

Researchers identify elusive gene responsible for Grey Platelet Syndrome

Researchers have identified an elusive gene responsible for Grey Platelet Syndrome, an extremely rare blood disorder in which only about 50 known cases have been reported. As a result, it is hoped that future cases will be easier to diagnose with a DNA test.

26 Jul 2011

Fragile X syndrome study to reveal more

Fragile X syndrome is the most common inherited cause of intellectual disability in the world. Medical experts, including the Mater Hospital's Dr Helen Heussler, are today launching a new push to uncover the secrets of a disorder that affects a child born in Australia every week. Fragile X is passed from parent carriers who often exhibit very few symptoms. Estimates suggest more than 100,000 Australians either carry the gene mutation that causes Fragile X or have the syndrome, yet the vast majority have not been diagnosed, according to the Fragile X Association of Australia.

25 Jul 2011

Promising drug for Duchenne muscular dystrophy

Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.

25 Jul 2011

Illumina begins to ship HumanOmni5-Quad DNA Analysis BeadChip

Illumina, Inc. today announced that it has begun shipping the HumanOmni5-Quad DNA Analysis BeadChip (Omni5), the new flagship array of the Omni family of microarrays.

From Illumina, Inc. 25 Jul 2011

Two genetic variations can identify children at higher risk of radiation-induced second cancers

A genome-wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment.

25 Jul 2011

Many doctors do not appropriately offer breast and ovarian cancer counseling

A new analysis has found that many doctors report that they do not appropriately offer breast and ovarian cancer counseling and testing services to their female patients. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to encourage these services for high-risk women and discourage them for average-risk women.

25 Jul 2011

First high-resolution genetic maps for African American populations

UCLA life scientists and colleagues have produced one of the first high-resolution genetic maps for African American populations. A genetic map reveals the precise locations across the genome where DNA from a person's father and mother have been stitched together through a biological process called "recombination." This process results in new genetic combinations that are then passed on to the person's children.

25 Jul 2011

Sigma Life Science releases breast cancer-specific knockout and knockin cell lines for drug research

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich, today announced the expansion of its CompoZr® Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research.

22 Jul 2011

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Sangamo BioSciences, Inc. announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences (PNAS), represents a significant advancement in the development of improved, less immunogenic animal tissue as a source for transplant into humans.

22 Jul 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

Humans' desire to kill rats has only made them stronger

Over millennia, mice have thrived despite humanity's efforts to keep them at bay. A Rice University scientist argues some mice have found two ways to achieve a single goal -- resistance to common poison.

22 Jul 2011

Scientists discover new bases of DNA

For decades, scientists have known that DNA consists of four basic units -- adenine, guanine, thymine and cytosine. Those four bases have been taught in science textbooks and have formed the basis of the growing knowledge regarding how genes code for life.

22 Jul 2011

Insight into Fragile X Syndrome and autism

Researchers now have a much clearer understanding of how mutations in a single gene can produce the complex cognitive deficits characteristic of Fragile X Syndrome, the most common inherited form of intellectual disability.

22 Jul 2011

Roche's cobas KRAS Mutation Test for colorectal cancer now available in Europe

Roche announced today that the cobas KRAS Mutation Test is now commercially available in Europe for use in colorectal cancer.

22 Jul 2011

First genome-wide mapping of DNA modification in embryonic stem cells

Stem cell researchers at UCLA have generated the first genome-wide mapping of a DNA modification called 5-hydroxymethylcytosine (5hmC) in embryonic stem cells, and discovered that it is predominantly found in genes that are turned on, or active.

22 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

Researchers discover novel combination of two mutations in a patient with ADHD

Often enough, in science as in life, unexpected knowledge has a personal impact. Researchers seeking rare gene variants in just a few individuals with attention-deficit hyperactivity disorder (ADHD) discovered that one patient had a novel combination of two mutations.

21 Jul 2011

World's best genetic map now built in African-Americans

A group of researchers from the University of Oxford, Harvard Medical School and the University of Mississippi Medical Center has constructed the world's most detailed genetic map, a tool scientists can use to better understand the roots of disease and how DNA is passed generationally to create diversity in the human species.

21 Jul 2011